A sterile pharmaceutical formulation for use in treatment of a patient in need thereof is disclosed, which comprises:(a) docetaxel, or a pharmaceutically acceptable salt thereof, wherein the docetaxel or pharmaceutically acceptable salt thereof is in an amount of about mg/mL to about 20 mg/mL(b) glycofurol or ethanol(c) one or more hydrotropes comprising d-alpha-tocopheryl polyethylene glycol succinate (TPGS), polyethylene glycol (PEG), propylene glycol (PG), or a mixture thereof and(d) waterwherein the formulation is substantially free of polysorbate surfactants and polyethoxylated castor oil and wherein the formulation is precipitate-free at about six hours andwherein the formulation may further comprise: (e) a buffer and (f) one or more antioxidants comprising alpha-lipoic acid.
